Payment overview · 2025
General Payments
$195.66
6 reported records · 5 companies
Healthcare provider profile · identity verified
Andrew Ross, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SALINA, KS · NPI 1598146409
Verified facts
What the public records show
CMS Open Payments records show Andrew Ross, M.D. received $195.66 in general payments during 2025 across 6 reported records.
Stryker Corporation accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $113.13 | 57.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.66 | 15.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.39 | 11.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.92 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.56 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $195.66 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $113.13 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $113.13 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 681 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 88 |
| Gabapentin | Gabapentin | 331 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 85 |
| Furosemide | Furosemide | 286 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 64 |
| Potassium Chloride | Potassium Chloride | 236 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 235 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 60 |
| Omeprazole | Omeprazole | 226 | 59 |
| Lisinopril | Lisinopril | 207 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 44 |
| Eliquis | Apixaban | 169 | 36 |
| Spironolactone | Spironolactone | 151 | 43 |
| Sertraline Hcl | Sertraline Hcl | 149 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 139 | 21 |
| Tramadol Hcl | Tramadol Hcl | 136 | 21 |
| Atenolol | Atenolol | 132 | 32 |
| Metformin Hcl | Metformin Hcl | 128 | 30 |
| Warfarin Sodium | Warfarin Sodium | 127 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 44 |
| Allopurinol | Allopurinol | 117 | 33 |
| Alendronate Sodium | Alendronate Sodium | 107 | 23 |
| Pregabalin | Pregabalin | 106 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 21 |
| Glipizide Er | Glipizide | 105 | 24 |
| Carvedilol | Carvedilol | 100 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 27 |
| Prednisone | Prednisone | 95 | 48 |
| Ezetimibe | Ezetimibe | 88 | 23 |
| Finasteride | Finasteride | 87 | 24 |
| Montelukast Sodium | Montelukast Sodium | 85 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 16 |
| Metformin Hcl Er | Metformin Hcl | 82 | 32 |
| Mirtazapine | Mirtazapine | 80 | 15 |
| Synthroid | Levothyroxine Sodium | 80 | 16 |
| Famotidine | Famotidine | 74 | 21 |
| Farxiga | Dapagliflozin Propanediol | 74 | 12 |
| Memantine Hcl | Memantine Hcl | 74 | 18 |
| Cephalexin | Cephalexin | 73 | 46 |
| Bupropion Xl | Bupropion Hcl | 71 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 69 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 16 |
| Trazodone Hcl | Trazodone Hcl | 67 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | suppressed |
| Simvastatin | Simvastatin | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 11 |
| Meloxicam | Meloxicam | 62 | 18 |
| Donepezil Hcl | Donepezil Hcl | 60 | 14 |
| Jardiance | Empagliflozin | 58 | suppressed |
| Valsartan | Valsartan | 57 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 11 |
| Baclofen | Baclofen | 51 | 15 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Estradiol | Estradiol | 49 | 21 |
| Ondansetron Odt | Ondansetron | 49 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 25 |
| Digoxin | Digoxin | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | 12 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 24 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | 11 |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Minoxidil | Minoxidil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $195.66 · 6 records | Stryker Corporation | AREXVY, BEXSERO, CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, Korlym, Ozempic, PEDIARIX, PENMENVY, Rybelsus, SHINGRIX, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error